Quarterly Results
GERN Earnings Forecast
Looking ahead, GERN remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 50.88M and an EPS of -0.03.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -8.78%, while EPS estimates have been Revise Downward by -3.25%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Downward by -17.21% . These revisions correlate with a 2.29% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in GERN long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how GERN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, GERN sees a +6.29% change in stock price 10 days leading up to the earnings, and a -0.88% change 10 days following the report. On the earnings day itself, the stock moves by -3.69%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -0.92% on the day following the earnings release and then changed by -0.92% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of GERN's latest earnings report for FY2025Q3?
GERN reported its FY2025Q3 earnings on 2025-11-05, showcasing a revenue of 47.23M against an estimate of 53.34M, resulting in a -11.46% surprise. The EPS was -0.03, surpassing the expected -0.03 by 0% . The stock experienced a -5.22% price change on the earnings day and a 0.87% change over the next five days, reflecting market reactions to the results.
How did GERN's stock price react after the FY2025Q3 earnings release?
Following GERN's FY2025Q3 earnings announcement on 2025-11-05, the stock price moved by -5.22% on the day of the release. Over the subsequent five days, it saw a 0.87% change. Historically, GERN's stock price tends to shift by an average of +6.29% in the 10 days leading up to earnings and -0.88% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for GERN for 2025/Q4?
For 2025/Q4, analysts estimate GERN’s annual revenue to reach 50.88M, while the EPS is projected at -0.03. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -8.78% and EPS estimates Revise Downward by -17.21% over the past three months, indicating analyst expectation in the company’s performance.
How does GERN's stock price correlate with earnings forecast revisions?
The correlation between GERN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -8.78%, while EPS estimates moved Revise Downward by -17.21% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from GERN's next earnings report?
Based on historical trends, GERN's stock price typically moves by +6.29% in the 10 days before its earnings and -0.88% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.03 and revenue of 50.88M.
What is the sentiment in Geron Corp (GERN) Q3 2025 Earnings Call Summary?
The earnings call reveals several negative factors: a 3% demand decrease for RYTELO, high operating expenses, and competitive pressures. While there is a significant increase in net product revenue, the timeline for the IMpactMF Phase III trial is lengthy, delaying potential market impact. The Q&A section highlights management's avoidance of specific guidance, which may concern investors. Although there is a 15% growth in prescribing accounts, the overall sentiment is negative due to financial pressures, competitive landscape, and lack of clarity on future growth timelines.

